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Autophagy lysosomal pathwayParkinson's disease (PD) is a common neurodegenerative movement disorder that affects increasing number
of elderly in the world population. The disease is caused by a selective degeneration of dopaminergic
neurons in the substantia nigra pars compacta with the molecular mechanism underlying this
neurodegeneration still not fully understood. However, various studies have shown that mitochondrial
dysfunction and abnormal protein aggregation are two of the major contributors for PD. In fact this notion
has been supported by recent studies on genes that are linked to familial PD (FPD). For instance, FPD linked
gene products such as PINK1 and parkin have been shown to play critical roles in the quality control of
mitochondria, whereas α-synuclein has been found to be the major protein aggregates accumulated in PD
patients. These ﬁndings suggest that further understanding of how dysfunction of these pathways in PD will
help develop new approaches for the treatment of this neurodegenerative disorder.+852 2358 1552.
ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction
Parkinson's disease (PD) is a common neurodegenerative move-
ment disorder that affects around 1% of the population over the age of
70 [1]. The disease was ﬁrst described in details by James Parkinson in
1817 about some of the clinical features he observed in his PD
patients. After almost two centuries of research on PD, it is now well-
established that the clinical symptoms of the disease is caused by a
selective degeneration of dopaminergic (DAergic) neurons in the
substantia nigra pars compacta (SNc) in the brainstem [1]. In addition
to the degeneration of DAergic neurons in SNc, mitochondrial
complex I dysfunction, increased indices of oxidative stress, and the
presence of intra-neuronal protein aggregates designated as Lewy
bodies (LBs) are commonly observed in the affected brain areas of PD
patients [1,2].
The recent understanding of PD pathogenic mechanism has been
greatly assisted by the studies of MPTP (1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine)-induced Parkinsonism and genes that are linked
to familial PD (FPD) [1,2]. MPTP induced-Parkinsonism was ﬁrst
reported in a group of drug addicts that developed PD after the
injection of a synthetic heroin in the 1980s. Later studies found that
after administration, MPTP can pass through the blood–brain barrier
and metabolized by monoamine oxidase to MPP+ [3]. MPP+, which
can be selectively uptaken by dopamine transporter, inhibits complex
I in the mitochondria and induces degeneration of DAergic neuronsthrough the excessive generation of free radicals [3]. Since the
discovery of MPTP, it has been widely used to establish various animal
models for the study of PD.
Another major advance in the study of PD is the identiﬁcation of
genes that are linked to FPD. PD is mostly sporadic, but clusters of PD
patients have been shown to be familial-linked. Altogether, 16 loci
have been described in the database of Online Mendelian Inheritance
in Man (OMIM) from the National Center for Biotechnology
Information (NCBI) (Table 1). Among these loci, six of them have
been extensively studied. These include α-synuclein (α-syn), parkin,
UCHL-1, PINK1, DJ1 and LRRK2 [1,4]. Genome-wide association studies
in Japan and Europe have found that there are strong associations of
genetic risk factors for PD at loci of α-syn, LRRK2 and PARK16,
indicating the importance of these genes in the pathogenesis of PD
[5,6]. In addition, functional studies of these FPD linked gene products
have supported the hypothesis that oxidative stress, mitochondrial
dysfunction and protein misfolding/aggregation are major contribu-
tors for PD pathogenesis [1,2,4].
2. Oxidative stress and mitochondrial dysfunction in PD
Increased indices of oxidative stress have been consistently
observed in post-mortem studies in PD patients [2,7]. The sources of
oxidative stress can be attributed to inﬂammatory response and
mitochondrial dysfunction in the brain [2,7]. Activation of microglia
can cause inﬂammatory response that activates inducible nitric oxide
synthase (iNOS) and contributes to oxidative stress in the affected
areas. Another more common and important source of oxidative
stress is from the mitochondria. Neurons are constantly requiring a
Table 1
The 16 FPD-linked loci that are documented in the OMIM database at the NCBI.
FPD type Gene locus Gene Inheritance
PARK1 4q21 α-synuclein Autosomal dominant
PARK2 6q25.2–27 Parkin Autosomal recessive
PARK3 2p13 Unknown Autosomal dominant
PARK4 4q21 α-synuclein/triplication Autosomal dominant
PARK5 4p14 UCHL1 Autosomal dominant
PARK6 1p36 PINK1 Autosomal recessive
PARK7 1p36 DJ1 Autosomal recessive
PARK8 12q12 LRRK2 Autosomal dominant
PARK9 1p36 ATP13A2 Autosomal recessive
PARK10 1p32 ? Autosomal dominant
PARK11 2q37.1 ? Autosomal dominant
PARK12 Xq21–q25 ? X-linked
PARK13 2p12 OmiHtrA2 Autosomal dominant
PARK14 18q11 ? ?
PARK15 22q12–q13 FBXO7 Autosomal recessive
PARK16 1q32 ? ?
936 W. Xie et al. / Biochimica et Biophysica Acta 1802 (2010) 935–941sufﬁcient supply of energy through ATP by the oxidative phosphor-
ylation in the mitochondria to maintain ionic gradient that is required
for the transmission of nerve impulse. However, at the same time,
mitochondrial activity is also a major source of reactive oxidative free
radicals. Various studies have suggested that mitochondrial dysfunc-
tion can contribute to increased levels of oxidative stress and can
affect neuronal survival in the process of neurodegeneration [2]. For
instance, complex I inhibition has been consistently observed in PD
patients and it has been suggested that increased generation of
reactive oxygen species (ROS) from the mitochondria through
complex I inhibition is a major contributor for the DAergic neuronal
cell death in PD [3]. This is illustrated clearly in the MPTP-induced
Parkinsonism in which inhibition of complex I in the mitochondria
leads to the production of free radicals and causes DAergic neuronal
degeneration [3]. More importantly, recent studies on FPD linked gene
products have shown that most of them can affect or regulate
different functional or physiological aspects of mitochondria.
2.1. α-syn
α-syn, the ﬁrst gene that was found to link to FPD, has been shown
to affect mitochondrial function by different mechanisms. α-syn is a
presynaptic protein and is also a major component of LBs [8,9]. Three
mutations in α-syn (A53T, A30P and E46K) and a gene triplication
have been found to cause autosomal dominant form of FPD [10–13].
Although α-syn is predominantly located to the cytosol, studies have
suggested that α-syn can associate with the mitochondria [14]. In
cellular models, expression of mutant α-syn has been shown to
induce mitochondrial depolarization and release of cytochrome c in
association with cell death, suggesting that the mitochondrial
permeability can be affected by mutant α-syn [15]. Interestingly,
biochemical studies have shown that mutations or abnormal
expression of α-syn can accelerate the formation of α-syn protoﬁbrils
or oligomers [16,17]. These oligomers or protoﬁbrils have been shown
to form pores within the lipid vesicles, providing the potential
mechanism of how α-syn can increase the mitochondrial permeabil-
ity in neurons [18–20].
From both cellular and animal models of PD, studies suggest that
α-syn can affect components of the electron transport chain (ETC)
and result in the generation of excessive ROS in DAergic neurons [21].
For instance, in mice over-expressing A53T human mutant α-syn,
mitochondrial DNA damage was detected in the neurons of brainstem
and spinal cord [22]. In addition, reduction of complex IV activity was
also found in spinal cord [22]. These results support that α-syn can
affect the normal function of ETC in the mitochondria [22]. Moreover,
α-syn null mice are resistance to the MPTP-induced degeneration of
DAergic neurons, which supports that α-syn is contributing to thedegeneration of DAergic neurons in PD through its action on the ETC
in the mitochondria [23,24].
Interestingly, study has also found that α-syn possesses neuro-
protective function in a model of neurodegenerative disease [25]. In
mice, deletion of a synaptic protein cysteine-string protein-α (CSP-α),
causes defects in synaptic transmission and progressive neurodegen-
eration [25]. Unexpectedly, transgenic expression of α-syn abolishes
the neurodegenerative phenotype observed in CSP-α knockout mice,
suggesting thatα-syn can have neuroprotective function in themouse
brain [25].2.2. PINK1 (PTEN-induced kinase 1)
PINK1 is the ﬁrst mitochondrial protein that mutations are
associated with FPD [26,27]. It is a ubiquitously expressed protein
that shows punctuated cytoplasmic staining pattern and co-localizes
with mitochondria [28]. However, recent studies have suggested that
full-length and an N-terminal truncated form of PINK1 can be found in
the cytosol and microsome fractions in the cells [29,30]. PINK1
possesses a highly conserved serine–threonine kinase domain and a
carboxyl-terminus domain that regulates its autophosphorylation
activity [26,27]. All the FPD linked PINK1mutations so far have shown
to involve the kinase domain, suggesting the importance of PINK1's
kinase activity in the pathogenesis of PD [26,27].
Various studies have shown that PINK1 can maintain proper
function of mitochondria under stressful conditions and provide
neuroprotection against oxidative stress [1,7]. For instance, over-
expression of PINK1 can protect against mitochondrial dysfunction
and apoptotic cell death in neurons under various cellular insults
[26,31]. In contrast, deletion of PINK1 by RNA interference in neurons
was found to affect the normal morphology and function of
mitochondria [32,33]. The importance of PINK1 in the mitochondrial
function is best demonstrated by the Drosophila PINK1 model of PD.
Deletion of PINK1 in Drosophila resulted into the fragmentation of
mitochondrial cristae and enlargement of the mitochondria [34–36].
Physiologically, degeneration of muscle and DAergic neurons, loco-
motor deﬁcits, male sterility and shortening of lifespanwere observed
in these PINK1 deletion mutants [34–36]. These results suggest that
PINK1 is required for the normal function of mitochondria. Interest-
ingly, deletion of another FPD linked gene parkin in Drosophila has
been shown to have similar phenotype as in PINK1 deletion mutant
[34–36]. More interestingly, over-expression of parkin was found to
rescue the effect of PINK1 deletion in Drosophila but not vice-versa,
indicating that parkin is functioning downstream of PINK1 [34–36].
Considerable effort has been made in understanding the role of
PINK1 in the physiological function of mitochondria. Recent studies
suggest that PINK1 can mediate its function through the regulation of
HtrA2 (also known as Omi) and TNF receptor-associated protein 1
(TRAP1) [37,38]. HtrA2 is a serine protease that is localized to the
mitochondria, but during apoptosis, it is released into the cytosol from
the mitochondria and binds to the inhibitor of apoptosis proteins
(IAPs) [39]. In mice, deletion of HtrA2 or mutation that impairs the
protease activity of HtrA2 causes neurodegenerative phenotype
which resembles PD [37,39]. Further studies on these mice suggest
that HtrA2 might have protective function for the mitochondria
[37,39]. A study has identiﬁed two HtrA2 mutations (G339S and
A141S) that affect its normal protease function in association with
FPD [40]. However, a more updated genetic study suggests that
mutations in HtrA2 are not associated with PD [41]. Interestingly,
phosphorylation of HtrA2, which increases its protease activity and
protects cells against cellular insults, is dependent on the normal
function of PINK1 [37]. In another study, TRAP1 was found to be
phosphorylated by PINK1 [38]. TRAP1 is a mitochondrial chaperone
and phosphorylation of TRAP1 by PINK1 suppresses the release of
cytochrome c from the mitochondria when the cells are under various
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its protective function through HtrA2 and TRAP1 pathways.
2.3. PINK1 and parkin in mitochondrial function
Initial studies that linked PINK1 and parkin in relation to
mitochondrial function were ﬁrst evident in phenotypes observed in
PINK1 and parkin deletion mutants of Drosophila [34–36]. Both PINK1
and parkin deletion mutants exhibit similar mitochondrial dysfunc-
tion phenotypes in Drosophila [34–36]. More importantly, over-
expression of parkin was found to rescue the mitochondrial
dysfunction phenotype observed in PINK1 deletion mutant, suggest-
ing that parkin is a downstream component for the PINK1 associated
pathway [34–36]. Later studies suggest that the PINK1 and parkin
pathway can promote mitochondrial ﬁssion which is critical for the
normal function of mitochondria in Drosophila [42,43].
Several recent studies have reported the mechanism of how PINK1
and parkin can play critical roles in the quality control ofmitochondria.
It was found that depolarization ofmitochondria is associatedwith the
accumulation of PINK1 in the mitochondria [44–46]. This PINK1
accumulation was found to recruit parkin into the damaged mito-
chondriawhich can subsequently inducemitophagy [44–46]. Different
mechanisms have been reported for howPINK1 and parkin can initiate
mitophagy for the clearance of damagedmitochondria. Vives-Bauza et
al. suggest that after depolarization ofmitochondria, PINK1 and parkin
modulates trafﬁcking of damaged mitochondria to the perinuclear
region for autophagy [44]. In another report by Geisler et al., it was
shown that parkinmediatedmitophagy is dependent on the formation
of Lys 27 and Lys 63 polyubiquitin linkages by parkin [45]. In addition,
it was found that parkin can target voltage-dependent anion channel 1
(VDAC1) for Lys 27 polyubiquitination [45]. Finally, both Lys 27
polyubiquitination of VDAC1 and recruitment of p62/SQSTM1, an
adaptor protein for the ubiquitin system and autophagy, by parkin are
required for the clearance of the damaged mitochondria through
mitophagy [45]. In the study by Ziviani et al., it was reported that in the
Drosophila, PINK1 recruits parkin into mitochondria and promotes
mitophagy through the ubiquitination of mitofusin (Mfn) [46]. Taken
together, these results show the importance of PINK1 and parkin in the
quality control of mitochondria through the clearance of damaged
mitochondria by autophagy [44–46].
3. Protein aggregation, the ubiquitin proteasomal system and the
autophagy lysosomal pathway in PD
One of the common pathological hallmarks of neurodegenerative
diseases is the presence of protein aggregates in the affected brain
areas. In PD, prominent protein aggregates are designated as LBs. LBs
are eosinophilic intracellular protein aggregates that are character-
ized by a dense core surrounded by a clear halo. Initial studies showed
that LBs are mostly ubiquitin positive, leading to the hypothesis that
the ubiquitin and proteasomal system (UPS) is involved in the
formation of LBs. The importance of protein aggregation and UPS
dysfunction in pathogenesis of PD is subsequently supported by the
identiﬁcation of FPD gene products that are directly linked to protein
aggregation or the UPS. For instance, the ﬁrst identiﬁed FPD gene
product α-syn was found to be the major component of LBs [8,9]. The
subsequent identiﬁcation of parkin, an E3 ligase in the UPS, in relation
to a cohort of autosomal recessive juvenile Parkinsonism (ARJP) in
Japanese patients provides another strong support for the involve-
ment of UPS dysfunction in PD [47–49].
3.1. α-syn aggregation and PD
Because of the ﬁnding that mutations in α-syn cause autosomal
dominant form of Parkinsonism [11], and α-syn is also the major
component of LBs [8,9], abnormal accumulation and aggregation ofα-syn have been suggested to be the major contributor for PD [50].
However, the molecular mechanism of how α-syn can form
aggregates and how aggregates can cause selective neuronal cell
death in SNc is not completely clear. For instance, it is still not
conclusive which form of α-syn aggregates is responsible for the
toxicity induced by α-syn in neurons. It was initially suggested that
visible aggregates such as LBs in the neurons were the major
cytotoxic species, however, more recent studies have shown that
oligomers of α-syn are the cytotoxic species that cause neurode-
generation in the DA neurons [50]. Various studies have shown that
wild type or FPD linked mutant α-syn can form beta-sheet
ﬁlamentous aggregates in vitro after prolonged storage in different
conditions [16,17]. In addition, nitration of α-syn and addition of
dopamine adduct on α-syn have been shown to affect the tendency
of α-syn to form different types of oligomers [51–53]. Over-expression
of α-syn has been shown to increase cytosolic dopamine level possibly
through the enhanced leakage of dopamine from the synaptic vesicles
[52,54,55]. This increased in cytosolic dopamine can then further
aggravate the formation of α-syn oligomer through the dopamine-
induced modiﬁcation [52,54,55]. Apart from nitration and dopamine
modiﬁcation, it was also found that phosphorylation ofα-syn at Ser 129
promotes ﬁbril formation and phosphorylated α-syn was found
in synucleinopathy lesions, suggesting that hyperphosphorylation of
α-syn might be another contributing factor in PD [56,57].
Interestingly, a new mechanism of how aggregation of α-syn can
be initiated and propagated has recently been proposed [58]. The idea
was ﬁrst initiated in the post-mortem studies of PD patients who
received transplant of embryonic dopamine neurons in a pilot study
to treat the disease in more than a decade ago [59,60]. The studies
were performed to determine the effectiveness of the transplantation
[59,60]. Strikingly, it was found that LB-like structure was present in
the transplanted embryonic dopamine neurons, suggesting that the
micro-environment within the brain of the patients can actually
initiate the pathological process of α-syn aggregation [59,60]. Based
on this observation, it was suggested that misfolded α-syn, like in the
prion disease, can transmit between cells and can initiate α-syn
aggregation in healthy neurons [58]. This hypothesis is supported by a
recent study which showed that α-syn can be transmitted between
neurons to induce the formation of LB-like inclusion and to promote
apoptosis in the affected neurons [61].
The accumulation of α-syn in cells is dependent on the production
and clearance of α-syn. Over synthesis of α-syn through gene
triplication has been shown to cause PD, supporting that high protein
levels of α-syn is a contributor to PD [12]. Equally important, the
maintenance of normal α-syn protein level is depending on the
proper function of the metabolic pathways that degrade α-syn. Two
pathways have been found to metabolize α-syn in the cells [62–64].
Initial study suggests that α-syn is degraded through the UPS [62,63].
However, later studies showed thatα-syn can also be cleared through
chaperone-mediated autophagy (CMA) [64–66]. Interestingly, both
α-syn mutants and dopamine modiﬁed α-syn have been shown to
affect their degradation by the CMA pathway, providing a potential
mechanism of how abnormal accumulation of α-syn can occur during
the pathogenesis of PD [64,65].
3.2. How protein aggregation contributes to PD
The mechanism of how protein aggregation can lead to neurode-
generation has been the center of debate in the ﬁeld of neurodegen-
eration. Initial studies have suggested that protein aggregates
represent a major cell death inducing factor in the process of
neurodegeneration [50,67]. However, more recent studies have
shown that protein aggregatesmight be a neuroprotectivemechanism
employed by the neurons for protection against more toxic protein
oligomers [50,67]. For instances, studies in both Alzheimer and
Huntington diseases have indicated that protein oligomers are the
938 W. Xie et al. / Biochimica et Biophysica Acta 1802 (2010) 935–941major toxic components in the process of neurodegeneration [68–70].
In PD, increasing evidence has also suggested that oligomers of α-syn
are the more cytotoxic components in the neurons [50,67].
Different mechanisms have been proposed for how α-syn
oligomers can induce DAergic neuronal degeneration in PD (Fig. 1).
For instance, it has been proposed that protoﬁbrils formed fromα-syn
oligomers have high afﬁnity to cellular membrane and can cause
leakage of molecules from cytoplasmic vesicle or organelles [54,55].
This can cause mitochondrial membrane depolarization, inﬂux of
calcium to the cytoplasm or leakage of dopamine from synaptic
vesicles in which all could ultimately lead to neuronal degeneration
(Fig. 1) [20,55,71–73]. In addition, other studies have suggested that
α-syn can inhibit complex I of mitochondria and this can result in the
generation of excessive reactive oxygen free radicals that can
compromise neuronal survival (Fig. 1) [21,74,75]. Moreover, studies
have also suggested that α-syn oligomers can inhibit proteasomal
function which can affect the clearance of α-syn oligomers and
therefore further aggravate the degenerative process (Fig. 1) [76,77].
Other studies have also found that α-syn can affect vesicle trafﬁcking
and thismight also involve the oligomers ofα-syn [78–80]. Altogether,
these studies suggest that the oligomeric form of α-syn might be the
major toxic species andmultiplemechanismsmight be involved in the
process of neurodegeneration.
3.3. UPS dysfunction and PD
It is well-known that misfolded and aggregated proteins are
cleared by the UPS. If the normal function of UPS is impaired,
accumulation of highly toxic misfolded and aggregated proteinFig. 1.Molecular mechanisms of how α-syn protoﬁbrils can contribute to neurodegeneratio
α-syn can lead to the formation of protoﬁbrils. α-syn protoﬁbrils can induce leakage of DA
promote the formation of more α-syn protoﬁbrils through increasing accumulation of modi
which can result into the leakage of pro-apoptotic molecules that can promote neurodegenspecies will likely induce neuronal cell death. This notion is supported
by the observation that ubiquitin positive protein aggregates are
consistently observed in different neurodegenerative disorders.
Similarly, the involvement of UPS dysfunction in the pathogenesis of
PD was ﬁrst established by the observation that ubiquitin positive LBs
are observed in PD patients [50]. The important role of UPS
dysfunction in PD is then further supported by the identiﬁcation of
parkin mutations in a cohort of Japanese ARJP patients [47]. Later
studies showed that parkin is an E3 ligase in the UPS which targets a
number of proteins for ubiquitination [81]. Various studies have
shown that parkin can function as a multi-functional neuroprotective
protein against different cellular insults such as protein misfolding,
proteasomal inhibition or protein aggregation [81]. However more
recent studies showed that parkin together with PINK1 is required for
the quality control of mitochondria [44–46]. It will be interesting to
see how UPS and mitochondria through parkin and PINK1 can
contribute to the pathogenesis of PD.
In patients with idiopathic PD, post-mortem studies have found
that proteasomal activity in different brain areas is decreased [82].
This result suggests that proteasomal inhibition might be a potential
mechanism that leads to the neurodegeneration in PD [82]. However,
in studies that treated animal systematically with proteasomal
inhibitor, inconclusive results were obtained [83–87]. Nevertheless,
if UPS dysfunction is one of the contributing factors in the
pathogenesis in PD, facilitation of the UPS function might represent
a new approach for PD treatment. For instance, our recent study has
shown that facilitation of protein degradation through the lysine 48
polyubiquitin linkage can rescue α-syn-induced toxicity in a
Drosophilamodel of PD [88]. In this study, we found that enhancementn in PD. Mutation, nitration, dopamine (DA) modiﬁcation or abnormal accumulation of
, and inhibit complex I in the mitochondria and proteasome in the UPS. All these can
ﬁed or normal α-syn. α-syn protoﬁbrils can also increase permeability of mitochondria
eration.
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proteins and can prevent the accumulation of protein aggregates [88].
More importantly, we found that enhancement of lysine 48
polyubiquitin linkage can protect against α-syn-induced toxicity in
neurons [88]. These results support that UPS might be a potential
therapeutic target for the treatment of PD [88].
3.4. Autophagy lysosomal pathway (ALP) and PD
Apart from UPS, ALP is another pathway that is known to
metabolize misfolded or aggregated proteins. Increasing evidence
has suggested that dysfunction of ALP can also contribute to PD
[89,90]. For instance, mutations in ATP13A2, a lysosomal ATPase, have
been identiﬁed in a Chilean family with early-onset PD with dementia
[91]. In another study, it was also found that mutations in another
lysosomal enzyme, glucocerebrosidase, are associated with increased
risk of PD [92]. Together with the studies that shown parkin is
involved in the clearance of damaged mitochondria through mito-
phagy and CMA is responsible for the clearance of α-syn, it is clear
that ALP is playing an important role in PD. Interestingly, cross talk
between UPS and ALP has been suggested through different types of
ubiquitin linkages [93], suggesting these two pathways might co-
operate to metabolize misfolded or aggregated proteins. Taken
together, more studies will be needed to determine how dysfunction
of UPS and/or ALP can contribute to PD [93].
3.5. New therapeutic approaches for PD
Research in 1980s that characterized the function of basal ganglia
in relation to PD which led to the use of L-dopa for PD is an excellent
example of how basic research can contribute to the treatment of this
disorder. Although L-dopa treatment is known to have side effects
such as dyskinesia, it remains the standard treatment for PD. One of
the fundamental problems in treating PD is that no therapeutic
approach is available to stop or delay the degenerative process in the
DAergic neurons. Recent advances in PD research have improved our
understanding of the pathogenic mechanism of this disorder. For
instance, mitochondria dysfunction, protein aggregation, ALP and UPS
dysfunction seem to be the major contributors behind the pathogen-
esis of PD. The challenge now will be to develop new therapeutic
strategies for PD treatment by targeting on these pathways.
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